Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE: Sensipar and Low Dose Vitamin D vs. Escalating Vitamin D in Secondary Hyperparathyroidism
NCT00135304Phase 4Completed
- Sponsor
- Amgen
- Start
- Aug 2005
- Primary completion
- Oct 2006
01
Overview
Phase 4, randomised, open-label trial of cinacalcet in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Primary endpoint: Achievement of NKF-K/DOQI targets for biPTH and Ca x P. Started Aug 2005; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00135304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135304.